Ramadan: impact on diabetes and other chronic diseases

This Pearl is provided as free content subject to our terms and conditions click here

Ramadan: impact on diabetes and other chronic diseases


Ramadan: impact on diabetes and other chronic diseases

During Ramadan, many of our Muslim patients will want to fast, fasting being one of the five pillars of the Muslim faith. How best can we support them in this?

The fast of Ramadan lasts from dawn to sunset for a period of 29 or 30 days. Following the lunar calendar, the fasting month is brought forward by about 10 days each year, and currently falls during the UK spring months.

In 2024, Ramadan will start on 10 March and end on 9 April. During this time, people will generally eat two meals a day: one before sunrise (Suhoor) and one after sunset (Iftar). No fluids or food are taken during daylight hours. This includes water and, often, medicines too.

Impact of fasting

A BMJ Practice Pointer acknowledged that fasting may impact chronic disease control (BMJ 2022;376e:063613). The authors recommended a structured pre-Ramadan review for people with:

  • Diabetes .
  • Adrenal insufficiency.
  • Thyroid disease.
  • Cancer.
  • Epilepsy.
  • Severe enduring mental illness.
  • Eating disorders.
  • Those who are pregnant or breastfeeding.
  • Occupational factors, e.g. shift workers and those operating heavy machinery.

Many Muslims, even those who could seek exemption, want to participate in fasting in Ramadan. We will want to respect that decision and work with people to achieve the best outcomes.

  • Start planning for Ramadan at least 6–8w before: pre-Ramadan education reduces the risk of harm.
  • Dietary advice that applies to the rest of the year should be followed in Ramadan, but the meals, particularly Iftar (the evening meal), are often celebratory in nature and involve higher calorie and sugar intake than normal. Suhoor (the morning meal) is often relatively small, so, for some, drug dose adjustments are needed to get people through the day without problems.
  • Pay special attention to medications that can cause dehydration (diuretics) or hypoglycaemia (insulin/sulphonylurea), or that may be affected by change in routine (antiepileptics/thyroid medication).
  • Seek specialist input for patients where there is any uncertainty about how to safely manage fasting.

Consider a brief ‘trial’ fast in the months before Ramadan to monitor the effect on disease management. For example, this might be an opportunity to monitor blood glucose and adjust insulin dosing.

For those who cannot fast safely, there are other options permitted by religious leaders:

  • A delay in fasting to allow a period of acute illness or pregnancy/breastfeeding to pass.
  • Charity (fidyah) for those unable to make up their fasts.

The remainder of this article relates to diabetes (type 1 and 2) in Ramadan.

Diabetes management in Ramadan

In 2021, the International Diabetes Federation (IDF) (funded by an unrestricted educational grant by Sanofi) updated its helpful guide on diabetes during Ramadan. Here are the key points.

The main risks during Ramadan are of hypo- and hyperglycaemia, diabetic ketoacidosis and dehydration (which can lead to thrombosis).

Stratify patients into one of three categories – high, moderate and low risk – using the IDF-DAR risk calculator. Management is based on risk. As you look at the scoring system below, bear in mind that:

  • Those scoring ≤3 are considered low risk.
  • Those scoring 3.5–6 are moderate risk.
  • Those scoring >6 are high risk.
Risk factorScore
Diabetes type
Type 11
Type 20
Diabetes duration
<10y0
≥10y1
Hypoglycaemia
Hypoglycaemia unaware6.5
Recent severe hypoglycaemia5.5
Multiple weekly hypoglycaemic events3.5
Hypoglycaemia <once per week1
No hypoglycaemia0
Level of glycaemic control
HbA1c >75mmol/mol (9%)2
HbA1c 58–74mmol/mol1
HbA1c <58mmol/mol (7.5%)0
Type of treatment
Multiple daily mixed insulin injections3
Basal bolus/insulin pump2.5
Once-daily mixed insulin2
Basal insulin1.5
Glibenclamide1
Gliclazide/MR or glimepiride or repaglinide0.5
Other therapy not including SU or insulin0
Self-monitoring of blood glucose
Advised and not completed2
Completed suboptimally1
Completed as indicated0
Acute complications (DKA/HONK)
In past 3 months3
In past 6 months2
In past year1
No DKA/HONK0
Macrovascular complications
Unstable6.5
Stable2
None0
Renal complications
eGFR <30ml/min6.5
eGFR 30–45ml/min4
eGFR 45–60ml/min2
eGFR >60ml/min0
Pregnancy
Pregnant: poorly controlled6.5
Pregnant: well controlled3.5
Not pregnant0
Frailty and cognitive function
Frail or cognitive impairment6.5
70 and no home support3.5
Not frail0
Physical labour
Intense4
Moderate2
None0
Previous Ramadan experience
Overall negative1
No negative experience0
Fast duration (hours)
≥161
<160

On the basis of the score from the table above, the suggested management is as follows:

Management during Ramadan
High risk (score >6)Moderate risk (score 3.5–6)Low risk (score 0–3)
Should not fast.Should be advised not to fast.Should be able to fast.
If they wish to fast, they should:
  • Receive structured education.

  • Check blood glucose regularly (guidance does not specify what ‘regularly’ means, but moderate to low risk groups are expected to check sugar 1–2x a day, and type 1s at least 6x a day – decide frequency of monitoring based on risk).

  • Adjust medication dose as per tables below.

  • Be prepared to break the fast in case of hypo- or hyperglycaemia or other illness.
  • Before fasting:
  • Provide structured education.

  • Adjust medication dose as per tables below.

  • Check blood glucose 1–2x/day during fasting.
  • Patient education

    Pre-Ramadan education should take place a minimum of 6–8 weeks before Ramadan, and be repeated annually.

    It should involve:

    • A structured risk assessment.
    • Self-monitoring blood glucose training:
      • Teach how for those who might not normally do this as part of their diabetes management.
      • How to adjust medication depending on results (see below).
    • Dietary advice:
      • Divide daily calories between Suhoor and Iftar, plus 1–2 snacks if necessary.
      • Ensure meals are well balanced: 45–50% carbohydrate (ideally unrefined carbohydrates), 20–30% protein, <35% fat (preferably mono- and polyunsaturated).
      • Include low glycaemic index, high-fibre foods that release energy slowly before and after fasting, e.g. granary bread, beans, rice.
      • Include plenty of fruit, vegetables and salads.
      • Minimise foods that are high in saturated fats, e.g. ghee, samosas, pakoras. Use small amounts of oil when cooking, e.g. olive, rapeseed.
      • Avoid sugary desserts.
      • Keep hydrated between sunset and sunrise by drinking water or other non-sweetened beverages. Avoid caffeinated and sweetened drinks.
    • Exercise: avoid vigorous exercise (increased risk of hypos and dehydration), especially in the hours just before sunset.
    • Break the fast if:
      • Blood sugar <3.9 or >16.6.
      • Symptoms of hypo- or hyperglycaemia, or dehydration, develop.
      • Symptoms of acute illness develop.

    (In most countries, measuring blood sugar is not considered to be breaking the fast, but, in some areas, it is – ask!)

    Adjusting medication

    The following is a guide summarised from the International Diabetes Federation. Seek expert advice if you are uncertain, or there is significant hypo- or hyperglycaemia, or if the patient has other complications.

    Usually taken:During Ramadan
    MetforminOnce dailyTake with Iftar (evening meal)
    Twice dailyTake with Iftar and Suhoor (morning meal)
    Three times dailyTake morning dose with Suhoor
    Take lunchtime and evening doses together with Iftar
    Slow-release metforminOnce dailyTake with Iftar
    SulphonylureaOnce dailyTake with Iftar
    Twice dailyIf well controlled, take lower-than-usual dose with Suhoor
    Take normal dose with Iftar
    GliptinsNo dose adjustment needed
    PioglitazoneNo dose adjustment needed – take with Iftar
    Gliflozins (SGLT2 inhibitors)Use with caution but no dose adjustment needed. Take with Iftar. Increase fluids in non-fasting hours if possible.
    GLP-1sNo dose adjustment needed
    On multiple medicationsVariableThose on more than 3 medications are at higher risk of hypoglycaemia. Doses of insulin and sulphonylurea should be reduced by 25–50%.

    Insulin in Ramadan

    We strongly suggest you take advice on this unless you are confident about managing insulin doses in the context of the physiological changes that occur in fasting.

    Dose adjustments depending on blood sugar

    This is fractionally different from the dose adjustment above for pre-mixed insulin (the cut off is 7.2 not 7, for reasons that are not explained in the document).

    Fasting/pre-meal blood glucoseAdjust long-acting basal insulin by (this will be begin given with Iftar) or short-acting insulin by:
    <3.9 or symptoms of hypoglycaemiaReduce by 4 units
    3.9–5Reduce by 2 units
    5–7.2No change
    7.2–11.1Increase by 2 units
    >11.1Increase by 4 units

    When to check blood sugar

    In type 1 diabetes, patients should check pre-Suhoor (first meal of the day), mid-morning, noon, mid-afternoon, before the sunset meal of Iftar and before bed AND at any time when there are symptoms of hypoglycaemia.

    Ramadan: impact of diabetes and other chronic diseases
  • Plan ahead – think about this 4–6w before Ramadan as it may involve changing medication, particularly insulins.

  • Encourage a healthy diet, normal exercise, and modifying foods to include more slow-release carbohydrates and fibre.

  • Encourage blood sugar monitoring if symptoms of hypoglycaemia or feeling unwell.

  • Discuss the need to break the fast if hypos, or intercurrent illness or complications develop.

  • Adjust drug regimens as necessary.
  • Useful resources:
    Websites (all resources are hyperlinked for ease of use in Red Whale Knowledge)
  • IDF – DAR Risk Calculator (to help shared decision-making around fasting)

  • British Islamic Medical Association – Ramadan compendium (for health professionals)

  • British Islamic Medical Association – Ramadan and diabetes guidance launched by

  • Diabetes UK (patient factsheet)
  • This information is for use by clinicians for individual educational purposes, and should be used only within the context of the scope of your personal practice. It should not be shared or used for commercial purposes. If you wish to use our content for group or commercial purposes, you must contact us at sales@red-whale.co.uk to discuss licensing, otherwise you may be infringing our intellectual property rights.

    Although we make reasonable efforts to update and check the information in our content is accurate at the date of publication or presentation, we make no representations, warranties or guarantees, whether express or implied, that the information in our products is accurate, complete or up to date.

    This content is, of necessity, of a brief and general nature, and this should not replace your own good clinical judgment or be regarded as a substitute for taking professional advice in appropriate circumstances. In particular, check drug doses, side effects and interactions with the British National Formulary. Save insofar as any such liability cannot be excluded at law, we do not accept any liability for loss of any type caused by reliance on the information in these pages.

    For access to our full terms and conditions click here